Product Name: LGI1 antibody [N2C2], Internal
Applications: ICC/IF, WB
Predicted Target Size: 64 kDa (note) (2)
Positive Controls: 293T , A431 , H1299 , HeLa , HepG2 , Molt-4 , Raji
Form Supplied: Liquid
Concentration: 1 mg/ml (Please refer to the vial label for the specific concentration)
Purification: Purified by antigen-affinity chromatography.
Full Name: leucine-rich, glioma inactivated 1
Background: This gene is rearranged as a result of translocations in glioblastoma cell lines. The protein contains a hydrophobic segment representing a putative transmembrane domain with the amino terminus located outside the cell. It also contains leucine-rich repeats with conserved cysteine-rich flanking sequences. This gene is predominantly expressed in neural tissues and its expression is reduced in low grade brain tumors and significantly reduced or absent in malignant gliomas. Mutations in this gene result in autosomal dominant lateral temporal epilepsy. [provided by RefSeq]
Synonyms: EPITEMPIN antibody, EPT antibody, ETL1 antibody, IB1099 antibody, LGI1 antibody, epitempin-1 antibody, leucine-rich glioma-inactivated protein 1 antibody, “leucine-rich, glioma inactivated 1 antibody”
Cellular Localization: Secreted
CAS NO: 1427782-89-5
Product: BIO
Host: Rabbit
Clonality: Polyclonal
Isotype: IgG
Immunogen: Recombinant protein encompassing a sequence within the center region of human LGI1. The exact sequence is proprietary.
Antigen Species: Human
Species Reactivity: Human, Rat
Conjugation: Unconjugated
Storage Buffer: 0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Storage Instruction: Keep as concentrated solution. Aliquot and store at -20ÂșC or below. Avoid multiple freeze-thaw cycles.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Specificity:
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19797320?dopt=Abstract
